Open AccessInvestigation on the bisphosphonate and osseointegrated implants: a concise systematic review
Author(s) -
Luis Alonso Romero Urdiales,
Daniel Alfonso Yaguana Galarraga,
Régis Manzini
Publication year - 2022
Publication title -
mednext journal of medical and health sciences
Language(s) - English
Resource type - Journals
ISSN - 2763-5678
DOI - 10.54448/mdnt22203
Subject(s) - osteoporosis , osseointegration , medicine , dentistry , bone resorption , bisphosphonate , skeletal disorder , bone mineral , population , bone density conservation agents , bone density , bone remodeling , implant , surgery , environmental health
The most common bone disorder found by implant dentists is osteoporosis, which is a systemic skeletal disorder associated with aging, which is characterized by loss of bone mass, making bones fragile and more susceptible to fractures. The World Health Organisation has defined osteoporosis as a bone mineral density level greater than 2.5 standard deviations below the mean of young normal women. After 60 years of age, a third of the population has this disorder, it occurs twice as often in women than in men. It is estimated that 1.3 million fractures and 133,000 all hip fractures occur every year as a result of osteoporosis. The aim of this study was to discuss aspects of the pharmacological action of Bisphosphonates (BP) and their influence on the bone tissue when associated with treatment with dental implants. There are several types of treatments that prevent or prevent the progression of osteoporosis. So, BP, such as alendronate, are inhibitors of bone resorption. Act as controlling the development of osteoporosis by increasing the process of bone density and decreasing its reabsorption, often acting as supporting the process of osseointegration of dental implants.